New hope for rare blood cancers: interferon trial launches
NCT ID NCT07468916
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests ropeginterferon alfa-2b, a long-acting immune protein, in 35 adults with rare blood cancers like CMML and MDS/MPN overlap syndromes. The drug aims to slow cancer cell growth by boosting the immune system. Researchers will check safety, best dose, and how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropeginterferon alfa-2b
What this could lead to
If successful, this could provide a new treatment option for rare blood cancers like CMML and MDS/MPN overlap syndromes, potentially slowing disease progression.
What could go wrong
This is an early phase 2 trial with only 35 participants, so results may not apply to everyone. Side effects from interferon therapy, such as flu-like symptoms or fatigue, are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact